Travere Therapeutics Inc expected to post a loss of 56 cents a share - Earnings Preview

Travere Therapeutics

18/02/2025 21:52

* Travere Therapeutics Inc  TVTX.OQ   TVTX.O  is expected
to show
a rise in quarterly revenue when it reports  results on February
20 for the period ending December 31 2024
    * The San Diego California-based  company is expected to
report a
62.8% increase in revenue to $73.335 million from $45.06 million
a year ago, according to the mean estimate from 15 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Travere Therapeutics Inc
is
for a loss of 56 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Travere
Therapeutics Inc is $31.00​, above​ its last closing price
of $22.91. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.69       -0.68      -0.70     Missed  -3
 Jun. 30 2024  -0.87       -0.86      -0.91     Missed  -5.7
 Mar. 31 2024  -0.97       -0.99      -1.76     Missed  -77.6​
 Dec. 31 2023  -1.32       -1.27      -1.03     Beat    19.1
 ​​Sep.        -0.02       -0.14      -1.17     Missed  -719.7
 30 2023                                                
 Jun. 30 2023  -1.20       -1.14      -1.13     Beat    1​
 Mar. 31 2023  -1.16       -1.17      -1.27     Missed  -8.5
 Dec. 31 2022  -1.08       -1.07      -1.03     Beat    4.1
 This summary was machine generated February 18 at 21:52 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)